On May 9th, Dx&Vx held a new product launch conference in Wuhan. At this press conference, Dx&Vx released two new products, Bilitin (phencycular quinolium bromide nasal spray) and Fushanlong (ceftran neopentyl tablets), and launched SCSS, a digital operation system for primary medical institutions.
The scale of this new product launch conference is huge, specially invited You Xuejun, associate professor of Tongji Medical College of Huazhong University of Science and Technology, Pang Ran, chief physician of the Department of Urology of Guang'anmen Hospital of China Academy of Chinese Medical Sciences, and many other experts, Lang Gang, deputy general manager of China Resources Sanjiu Innovation Business Division, Liu Weiqiang, deputy general manager of China Resources Jiuzhong, Yang Hua, deputy general manager of Kunming Pharmaceutical Group Pharmaceutical Commercial Co., Ltd., Li Kunxuan, purchasing director of Dongguan Sinopharm Group Co., Ltd., Guangdong Province, Wang Jun, chairman of the Physician Union of Langya District, Chuzhou City, Zhang Shiguo, commercial procurement director of Gansu Deshengtang Pharmaceutical Co., Ltd., Li Hui, Vice President of Hunan Chujitang Pharmaceutical Group, Zheng Qiaoyan, General Manager of Business Department of Taizhou Ruirentang Pharmaceutical Co., Ltd., Fang Wanqing, General Manager of Shuyu Pharmaceutical Logistics (Zaozhuang) Co., Ltd., Ren Peng, Purchasing Director of Harbin Renmin Tongtai Pharmaceutical Chain Co., Ltd., Huang Chunhong, Vice President of Dingdang Smart Pharmacy (Shanghai) Co., Ltd., Pu Xianhao, CEO of Hanmi Group and Beijing Runmeikang Pharmaceutical Co., Ltd., Liu Chunzhi, General Manager of Wuhan Keli Pharmaceutical Co., Ltd., Chen Baogang, Deputy General Manager of Wuhan Keli Pharmaceutical Co., Ltd., Tong Liqiang, Deputy General Manager of Wuhan Keli Pharmaceutical Co., Ltd., Bai Zhengui, Director of Marketing Planning Department of Hanmi Group and Beijing Runmeikang Pharmaceutical Co., Ltd., as well as medical colleagues from all over the world attended the event to witness the wonderful moment of Dx&Vx's new product launch.
The new products on the market, Fushanlong and Bilitin, are two blockbuster products that Dx & Vx have entered the domestic antibacterial and anti-allergy drug markets respectively, which will bring new treatment options to patients in the domestic market in the antibacterial and anti-allergy drug markets, and will also leverage the market of more than 3 billion rhinitis drugs and 100 billion antibacterial drugs.
Dx&Vx's bilitin is the first non-hormonal, chemical Class 1 innovative drug developed in the field of allergic rhinitis (AR, also known as "allergic rhinitis") in the field of allergic rhinitis in China. The treatment of AR has outstanding effects, and the effect is rapid and comprehensive.
You Xuejun, associate professor of otolaryngology-head and neck surgery at Wuhan Tongji Hospital, introduced at the press conference: "Bilitin fills the gap of anticholinergic treatment in AR treatment, and uses multiple mechanisms of action to combat AR nasal symptoms, such as phencycular quinolium bromide against the neuroimmune mechanism of AR pathogenesis, selectively blocks the cholinergic pathway, and then inhibits the vagus nerve reflex, down-regulates parasympathetic nerve excitation, and inhibits inflammatory response, significantly improving runny nose, nasal congestion, nasal itching, and sneezing." Phase 3 clinical studies confirmed that the incidence of adverse reactions of phencycular quinolium bromide was comparable to that of placebo, and all adverse reactions were mild, without treatment, and could be relieved spontaneously. ”
With high clinical value and safety, the third-generation cephalosporin original agent Fushanlong has the characteristics of a wide antibacterial spectrum, especially in the field of bactericidal bacteria sterilization of gynecological infections.
Toyama Ryu for the treatment of laryngitis, tonsillitis; paranasal sinusitis; Tympanitis; Periodontitis, pericoronitis, palateitis; acute and chronic bronchitis, diffuse bronchiolitis, bronchiectasis; Pneumonia; pyelonephritis, cystitis, gonococcal urethritis; Uterine adnexitis, endometritis, intrauterine infection, Patho's adenitis, Bartho gland abscess are all applicable, and it can also be used in combination with Archie/Meihong, with low adverse reaction rate, kidney, bile double channel excretion, and it is not easy to accumulate in the body.
Pang Ran, chief physician of the Department of Urology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, further pointed out that Fushanlong has therapeutic advantages for urinary tract infections, especially complicated urinary tract infections, specific urinary tract infections, and upper urinary tract infections; It has potential therapeutic advantages in male germline infections, especially acute prostatitis and epididymitis; It is also useful in perioperative patients with stones and in patients with prostate biopsy, helping to increase surgical safety and reduce the risk of postoperative infection, particularly sepsis, respectively.
Liu Chunzhi, General Manager of Wuhan Keli Pharmaceutical Co., Ltd., said: "The launch of Fushanlong and Bilitin is an important milestone in the development of our company. We will continue to uphold the concept of "innovation, development and service" to provide patients with more high-quality and efficient treatment options. At the same time, we also look forward to working together with all partners to jointly promote the prosperity and development of the medical industry in mainland China. ”
Dx&Vx is not only committed to providing high-quality products for the market, but also pays attention to the development status of terminal channels, focusing on the current pain points of primary medical care, Dx&Vx has launched the SCSS smart diagnosis and treatment system to assist clinics in optimizing the allocation of medical resources, improving the efficiency of medical services, and realizing the comprehensive upgrade of the primary diagnosis and treatment service model through information technology.
The SCSS system can provide prescription management, inventory management, sales management and other services for primary medical institutions, and at the same time realize intelligent distribution through the function of air pharmacy to reduce storage costs. In addition, a knowledge base of Korean and American experts has been grafted to provide academic support for doctors. The SCSS system empowers grassroots medical institutions through multi-dimensional diagnosis and treatment platforms, supply chain platforms, doctor gas stations, and point malls, helping them achieve refined management and efficient operation. At present, SCSS has successfully connected to the ERP systems of 300+ commercial companies, truly realizing the seamless connection of the digital operation of "industry + business + Internet + clinic".
In addition, at the press conference, Dx&Vx also signed a cooperation agreement with KA customers to provide patients with more diversified, better and more convenient health solutions with multiple terminals, and write a new chapter in the growth of medicine.
As a pharmaceutical company, Dx&Vx has always adhered to the mission of serving patients and protecting their health, and is committed to providing better health protection for Chinese patients. We look forward to further improving the product structure and bringing more choices to the market and patients.
(Disclaimer: The content of this article is an advertisement or reprinted promotional information, and the relevant materials are provided by the advertiser, which only represents the author's personal views and has nothing to do with this website.) It is for readers' reference only and please verify the relevant content on your own. ）